Department of Medicine

(photo by Erin O. Smith)

Vanderbilt-Ingram researchers present cancer advancements at ASH 2025 

Established in 1958, ASH is the world’s largest professional organization for clinicians and scientists who study blood diseases. 

Large-scale integration of genomics, proteomics and clinical records identifies cancer risk proteins and potential therapeutics

A new study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights approved drugs with potential cancer preventive effects.

An initiative at VUMC is helping patients recover more quickly from major surgery, leave the hospital earlier and have fewer side effects from their pain management. (photo by Joe Howell)

Ketamine fails surgical recovery trial

In a large, placebo-controlled, randomized trial, the pain reliever ketamine posed side effects while failing to aid patient recovery after major surgery.

Timothy Sterling receives $5.7 million to study tuberculosis transmission

Using molecular and other data from both the bacterial and human sides of the equation, a multi-institutional team will develop prediction models of TB transmission.

Protein plays dual roles in repairing damaged kidney

These findings were unexpected and demonstrate that the actin cytoskeleton repairs cell organelles like mitochondria in a regulated way.

Andrew DeFilippis, MD

Andrew DeFilippis named director of VUMC’s Division of Cardiovascular Medicine

He serves as associate chief of staff at Vanderbilt University Hospital and served as the medical director of the Cardiovascular Intensive Care Unit from 2020 to 2025.

1 2 3 123